Late-stage clinical upside overshadowed by severe cash shortage
- SELLAS is a pre-revenue biotech, so investor returns depend entirely on trial wins and funding.
- The lead drug GPS passed a Phase 3 interim analysis in January 2025 and nears its final reading.
- SLS009 met all primary endpoints in a Phase 2 trial and showed median overall survival of 8.8 to 8.9 months in named cohorts.
- The company carries a going concern warning and relies on dilutive stock sales to survive.
- An arbitrator dismissed milestone claims against 3D Medicines in July 2026, removing a key cash catalyst and adding legal fees.
Two clinical shots, one thin wallet
SELLAS is a high-risk biotech with real clinical potential. The lead drug, GPS, is in the Phase 3 REGAL study for acute myeloid leukemia, or AML. That trial passed its planned interim look in January 2025 and kept going without changes. By December 26, 2025, the trial had reached 72 deaths, placing it very close to the 80 needed for the final readout.
The second asset, SLS009, provides a strong secondary catalyst. In July 2025, SELLAS said SLS009 met all primary endpoints in a Phase 2 trial in relapsed or refractory AML. Median overall survival was 8.9 months in AML MR patients and 8.8 months in patients relapsed or refractory to venetoclax-based regimens at the 30 mg twice-weekly dose. The company compares that with a historical benchmark of about 2.4 months.
The bear case remains anchored by severe liquidity constraints. SELLAS operates with a going concern warning, generates no steady product sales, and depends entirely on selling stock. If GPS misses its final survival goal, the company may lack the financial runway to execute the wider SLS009 plan without devastating dilution.
The financial outlook worsened in July 2026 when an arbitrator dismissed the company claims against 3D Medicines. This deprived SELLAS of millions in expected non-dilutive capital and forced it to pay roughly one million dollars in legal fees, increasing the pressure to raise funds externally.
Licenses in, raises cash, runs trials
SELLAS does not sell an approved drug today. It licenses or acquires cancer drug candidates, pays to move them through clinical trials, and hopes to create value through regulatory approval, partnerships, or future sales.
GPS was licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, a marker found in many tumors. SLS009 was licensed from GenFleet Therapeutics and is a selective CDK9 inhibitor, meaning it is designed to block a cell-cycle target that some cancer cells need to survive.
The company previously hoped to fund operations by out-licensing regional rights. Its GPS deal with 3D Medicines covers Greater China, but that partnership soured. In July 2026, an arbitrator dismissed SELLAS claims for milestone payments and ordered the company to pay legal fees, eliminating a major potential cash source.
Without milestone payments, funding relies almost entirely on public equity offerings and registered direct offerings. That keeps trials alive, but it regularly shrinks each existing shareholder stake.
Pipeline bets to watch
GPS in AML maintenance
GPS is the lead program. Its Phase 3 REGAL study passed the January 2025 interim analysis and is waiting for the final analysis at 80 events.
SLS009 in relapsed or refractory AML
SLS009 met all primary endpoints in its Phase 2 r/r AML trial. SELLAS reported median overall survival of 8.8 to 8.9 months in specific cohorts.
SLS009 in frontline AML
Following FDA guidance, SELLAS is advancing SLS009 into a randomized 80-patient Phase 2 study in first-line AML, which could significantly widen the addressable market.
SLS009 in lymphoma
SLS009 has also shown encouraging lymphoma data. In a Phase 2a combination study with zanubrutinib, SELLAS reported a 67 percent overall response rate.
GPS Greater China rights
SELLAS out-licensed GPS rights in Greater China to 3D Medicines. The value of this deal evaporated in July 2026 when an arbitrator dismissed all milestone claims.
One reported business
SELLAS reports as a single biopharmaceutical development segment, according to its 2026 Q2 filing. The company does not break out separate revenue streams.
What can break the story
REGAL final miss
High impact · Medium oddsGPS is the lead asset, and the REGAL trial is close to its final 80-event analysis. Passing the interim analysis lowered risk, but it did not prove final survival benefit. A failed final readout would hurt the main approval path and make future fundraising incredibly difficult.
Cash runs short
High impact · High oddsSELLAS operates under a going concern warning and has no steady product revenue. The loss of the 3D Medicines arbitration removes a key source of non-dilutive capital. More equity offerings will be needed to keep the company alive, which will dilute current investors.
SLS009 data does not repeat
High impact · Medium oddsThe Phase 2 SLS009 AML data look promising, but later studies may not match early cohort results. The frontline AML study is a bigger and more demanding test. Safety, survival, and response rates all need to stay strong in larger pools of patients.
Partner and rights limits
Medium impact · Medium oddsSELLAS does not own every right in every region. While the 3D Medicines partnership for Greater China ended poorly, SLS009 China rights still remain with GenFleet. These limits can reduce future economics or complicate global strategy.
In one breath
Does SELLAS have an approved drug?
No. SELLAS is a clinical-stage company. Its value depends entirely on trial results, regulatory decisions, and its ability to raise money.
What is the biggest near-term catalyst for SLS stock?
The biggest clinical catalyst is the final Phase 3 REGAL readout for GPS at 80 events. Investors are also watching early data from the newly initiated SLS009 frontline AML trial.
Why does SLS009 matter if GPS is the lead drug?
SLS009 gives SELLAS a second major shot on goal. It met all primary endpoints in a Phase 2 r/r AML trial and is moving into a first-line AML Phase 2 study after receiving FDA guidance.
Why is SELLAS considered high risk?
The company has no steady product revenue, carries a going concern warning, and relies on dilutive financing. A bad GPS readout or a funding gap could sharply reduce the stock price.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- August 30, 2026
- Score data
- September 27, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near SELLAS Life Sciences Group, Inc. in Finn's Biotechnology industry ranking.
